Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX4I9D)

• Drug Name: 11-Heptanoyloxy-N-n-propylnoraporphine Drug Info
• Synonyms: CHEMBL516580; 11-Heptanoyloxy-N-n-propylnoraporphine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44579031
  TTD Drug ID: DMX4I9D

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[2]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[3]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[4]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[5]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[6]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[7]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[8]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[9]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[10]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[11]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[12]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[13]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[14]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[15]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[16]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[17]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[18]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[19]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[20]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[1]
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[1]

References

• [1] N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
• [2] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [5] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [6] Clinical pipeline report, company report or official report of Lundbeck.
• [7] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [8] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [9] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [10] Clinical pipeline report, company report or official report of Lundbeck
• [11] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [12] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [13] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [14] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [15] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [16] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [17] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [19] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [20] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.